367 related articles for article (PubMed ID: 25192804)
1. Hyperuricemia and cardiovascular disease risk.
Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
[TBL] [Abstract][Full Text] [Related]
2. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
3. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
4. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
5. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
7. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
Harzand A; Tamariz L; Hare JM
Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
9. Uric acid and oxidative stress: relative impact on cardiovascular risk?
Strazzullo P; Puig JG
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):409-14. PubMed ID: 17643880
[TBL] [Abstract][Full Text] [Related]
10. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
12. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
13. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Hosoya T; Ohno I
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options.
Doehner W; Landmesser U
Semin Nephrol; 2011 Sep; 31(5):433-40. PubMed ID: 22000650
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
17. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
18. [The uric acid cardio-nephropathy].
Viazzi F; Bonino B; Cappadona F; Pontremoli R
G Ital Nefrol; 2017 Mar; 34(Suppl 69):41-48. PubMed ID: 28682028
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
